Enzalutamide-induced “BRCAness” and PARP inhibition is a synthetic lethal therapy for castration-resistant prostate cancer

Cancers with dysfunctional mutations in BRCA1 or BRCA2, most commonly associated with some breast cancers, are deficient in the DNA damage repair pathway called homologous recombination (HR), which makes them exquisitely vulnerable to poly(ADP-ribose) polymerase (PARP) inhibitors, such as olaparib....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sci Signal
Hauptverfasser: Li, Likun, Karanika, Styliani, Yang, Guang, Wang, Jiangxiang, Park, Sanghee, Broom, Bradley, Manyam, Ganiraju C., Wu, Wenhui, Luo, Yong, Basourakos, Spyridon, Song, Jian H., Gallick, Gary E., Karantanos, Theodoros, Korentzelos, Dimitrios, Azad, Abul Kalam, Kim, Jeri, Corn, Paul G., Aparicio, Ana M., Logothesis, Christopher J., Troncoso, Particia, Timothy, Heffernan, Toniatti, Carlo, Lee, Hyun-Sung, Lee, Ju-Seog, Zuo, Xuemei, Chang, Wenjun, Yin, Jianhua, Thompson, Timothy C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5855082/
https://ncbi.nlm.nih.gov/pubmed/28536297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.aam7479
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge